ClinicalTrials.gg
CompletedNCT06845163DAPA-DMEUpdated Oct 26, 2026

Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema

A Phase 2 interventional study of Dapagliflozin and Anti-VEGF drug in Diabetic Macular Edema and Center-involved Diabetic Macular Edema, sponsored by Alexandria University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Alexandria University · Phase 2, Interventional, and Treatment

How we know

Updated Oct 26, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Macular Edema with a site in Egypt — 5 open to participants now, 5 under way, none of them phase 3. Macular Edema · Egypt.

Enrollment
6th of 17
56 · median 50
Started
2025
with 2 others
Phase 2
2 of 22
1 open now
Registered
18th of 22
by date
Lead sponsor
2 of 22
Alexandria University

Among the 22 studies in Macular Edema with a site in Egypt, this one is the 6th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 2, and was the 18th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

5 of the 22 studies in Macular Edema with a site in Egypt are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Macular Edema with a site in Egypt, or all of them as a file.
02

Study summary

The purpose of this clinical study is to explore the efficacy of dapagliflozin as an adjunct to intravitreal anti-vascular endothelial growth factor (anti-VEGF) for enhanced reduction of retinal thickness and vision improvement in patients with diabetic macular edema. The main question the study aims to answer is: Does dapagliflozin reduce the thickness of the macula when combined with the standard of care intravitreal anti-VEGF therapy more than the intravitreal anti-VEGF therapy alone?

Read the detailed description

Some evidence in the literature suggests that sodium glucose co-transporter 2 (SGLT2) inhibitors may be beneficial in reducing diabetic macular edema. The objective of this clinical trial is to investigate the efficacy and safety of dapagliflozin when combined with intravitreal aflibercept injections in the management of patients with type II diabetes mellitus and center-involved diabetic macular edema (ci-DME). This randomized, double-blind, parallel group, active control design, clinical trial, is investigating the effect of oral dapagliflozin 10 mg given once daily in addition to intravitreal aflibercept versus intravitreal aflibercept alone on reducing macular central subfield thickness (CST) and improving visual acuity in diabetic patients with ci-DME.

03

Conditions studied

  • Diabetic Macular Edema
  • Center-involved Diabetic Macular Edema

Browse trials for

Keywords

  • Diabetic Macular Edema
  • center-involved diabetic macular edema
  • Anti-VEGF
  • Aflibercept
  • EYLEA
  • Dapagliflozin
  • Forxiga
  • SGLT2 inhibitor
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

  • Type II diabetes mellitus patients, treated with premixed insulin and metformin, and diagnosed with center-involved diabetic macular edema (CiDME)
  • Presence of retinal thickening involving the center of the fovea (CiDME) in the study eye on Optical Coherence Tomography (OCT) Heidelberg Spectralis; If both eyes are eligible, the eye with the greater central subfield thickness on OCT is selected as the study eye.
  • Decreased visual acuity primarily attributable to DME
  • Clear ocular media and pupillary dilation for adequate retinal imaging
  • Ability to understand the study procedures and willingness to provide written

Study participant exclusion criteria:

  • Patients below 18 years old and patients above 85 years old
  • Patients with type I diabetes mellitus (Insulin dependent diabetes mellitus IDDM)
  • Pregnant women and lactating women diagnosed with diabetes or intending to become pregnant in the next 12 months
  • Patients who had myocardial infarction within 3 months prior to screening
  • Patients who had (TIA), ischemic or hemorrhagic stroke within 3 months prior to screening
  • Patients with poorly controlled diabetes mellitus, defined as patients having glycosylated () level of ≥12% at screening or patients who were hospitalized for diabetic ketoacidosis or hyperosmolar coma within 4 months prior to screening
  • Patients with estimated (eGFR) \< 30 mL/min/1.73 m2 at screening
  • Patients with severe hepatic impairment of Child-Turcotte-Pugh class C at screening
  • Patients treated with antidiabetic drugs thiazolidinediones (TZD) (rosiglitazone and pioglitazone) prior to screening
  • Patients who were receiving SGLT2 inhibitors (e.g., dapagliflozin, canagliflozin, or empagliflozin) within 3 months prior to screening
  • Known allergy or to any component of the study drugs
  • Current or previous participation in another clinical study involving the systemic or ocular administration of an drug or device within 6 months of screening

Study eye exclusion criteria:

  • Macular edema caused by other conditions than diabetic macular edema or coexisting with DME such as retinal vein occlusion, choroidal neovascularization (CNV), or uveitic cystoid macular edema
  • History of postoperative cystoid macular edema (Irvine-Gass syndrome)
  • Cataract extraction within 3 months prior to screening
  • Patients who had previous macular laser treatment
  • Patients who had peripheral panretinal photocoagulation laser (PRP) treatment within 6 months prior to screening
  • Patients who have been treated with intravitreal anti-VEGF or intravitreal within 6 months prior to screening
  • The use of corticosteroids or non-steroidal anti-inflammatory eye drops within 1 month prior to screening
  • Patients on topical prostaglandin analogs (e.g., latanoprost, travoprost, ioprost, or tafluprost) at screening
  • History of vitrectomy or scleral buckling
  • Presence of diffuse vitreomacular traction or thick epiretinal membrane on OCT causing significant traction
  • Presence of tractional retinal detachment involving the macula and requiring vitrectomy
  • Presence of other associated macular pathology (e.g., macular scars or macular holes) on OCT
  • Presence of rubeosis iridis
  • Signs of hypertensive retinopathy (arterioral spasm or silver wiring of blood vessels)
  • Presence of glaucoma
  • Aphakia
  • Yttrium aluminum garnet (YAG) laser capsulotomy within 3 months prior to screening
  • Patients diagnosed with ocular surface infections until treated prior to receiving the intravitreal injections

Non-study eye exclusion criteria:

  • The non-study eye receiving simultaneous intravitreal anti-VEGF treatment with the study eye
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Treatment group

    The treatment group will receive oral dapagliflozin 10 mg daily in addition to standard of care intravitreal aflibercept injections.

    Drug: Dapagliflozin · Drug: Anti-VEGF drug

  • Active comparator
    Control group

    The control group will receive standard of care intravitreal aflibercept injections.

    Drug: Anti-VEGF drug

Interventions

  • Dapagliflozin 10 mg will be given orally once daily for three months.

    Also known as: Forxiga 10 mg

  • DrugBevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Aflibercept 2 mg (0.05 ml) will be administered by intravitreal injection every month for three consecutive months.

    Also known as: Aflibercept (Eylea)

06

What researchers measure

Primary outcomes

  1. Mean central subfield thickness (CST)

    The reduction in mean central subfield thickness (CST) from baseline will be determined using Optical Coherence Tomography (OCT) and compared between study groups.

    Time frame: Baseline, 3 months

  2. The best-corrected visual acuity (BCVA)

    The improvement in the best-corrected visual acuity (BCVA) from baseline will be recorded and compared between study groups.

    Time frame: Baseline, 3 months

Secondary outcomes

  1. Percentage of patients with persistent macular edema

    The number of patients with persistent macular edema who are indicated to continue intravitreal anti-VEGF therapy beyond the initial 3 injections will be compared across study groups.

    Time frame: 3 months

  2. Retinal anatomical changes

    Retinal anatomical changes such as the improvement of cystoid macular spaces and resolution of subretinal fluid will be determined on OCT.

    Time frame: Baseline, 3 months

  3. Visual impairment patient reported outcome

    Patient reported outcome measures for visual impairment will be reported at baseline and after receiving interventions, using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25), and compared across study groups.

    Time frame: Baseline, 3 months

  4. Incidence of adverse events

    Systemic and ocular adverse events will be recorded and compared across study groups to assess the safety profile of the interventions.

    Time frame: 3 months

  5. Measuring the levels of some inflammatory cytokines in the aqueous humor

    The routinely withdrawn aqueous humor samples from patients with DME during intravitreal anti-VEGF injection will be collected and analyzed. The levels of inflammatory cytokines VEGF-A, interleukin (IL)-6, monocyte chemoattractant protein 1 (MCP-1), and tumor necrosis factor (TNF)-α, will be quantified, using multiplex protein analysis, and compared between the study groups.

    Time frame: Baseline, 2 months

07

Study locations

1 site
  • Alexandria Main University Hospital, The Ophthalmology Department, Faculty of Medicine, Alexandria University
    Alexandria, Alexandria Governorate, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Jul 2026, 17 months.

Of 50 phase 2 interventional studies under Macular Edema, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 17 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Mar 2026 → Jul 2026 and completion Aug 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Feb 25, 2025
StartActual
Feb 8, 2025
Primary completionActual
Jul 14, 2026was Mar 2026
CompletionActual
Jul 14, 2026was Aug 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 26, 2026
Sites
1 site added, 1 site removed
Show site
  • Alexandria Main University Hospital, The Ophthalmology Department, Faculty of Medicine, Alexandria University · Alexandria, Egypt
Show 1 removed
  • Alexandria Main University Hospital, The Ophthalmology Department, Faculty of Medicine, Alexandria University · Alexandria, Egypt
Oct 26, 2026
Primary completion
Mar 2026→Jul 14, 2026 (actual)
Oct 26, 2026
Study completion
Aug 2026→Jul 14, 2026 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Alexandria Main University Hospital, The Ophthalmology Department, Faculty of Medicine, Alexandria University · Alexandria, Egypt
    Show 1 removed
    • Alexandria Main University Hospital, The Ophthalmology Department, Faculty of Medicine, Alexandria University · Alexandria, Egypt
    Primary completion Mar 2026→Jul 14, 2026 (now actual)
    Study completion Aug 2026→Jul 14, 2026 (now actual)
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06845163
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Feb 8, 2025
Primary completion
Jul 14, 2026
Completion
Jul 14, 2026
Last update
Oct 26, 2026

Study contacts

Amira A. Nayel, MSc
principal investigator · Clinical researcher and PhD student at the Faculty of Pharmacy, Alexandria University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion